CAMBRIDGE ANTIBODY, ABBOTT SETTLE HUMIRA DISPUTE

Abbott Laboratories will pay more than $300 million to settle a dispute with U.K. biotechnology company Cambridge Antibody Technology Group Plc over the Humira arthritis treatment. Shares in CAT rose as much as 8.9 percent. Abbott Park, Illinois-based Abbott will pay $255 million to Cambridge Antibody as well as five annual payments of $9.375 million, the companies said today. Abbott will cut Cambridge Antibody's royalty on the drug to 2.688 percent of sales from 5.1 percent.

Bloomberg (http://www.bloomberg.com/apps/news?pid=10000102&sid=a2yqb7xLc3XA&refer=uk)